What are HER2-targeting antibody-drug conjugate drugs?

HER2-targeting antibody-drug conjugate drugs are pharmacologic agents that share a common mechanism (typically targeting HER2). 0 are currently marketed, with 3 more in clinical development.

HER2-targeting antibody-drug conjugate

0 marketed 2 in Phase 3 1 in Phase 2

This page covers all HER2-targeting antibody-drug conjugate drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting HER2.

Targets

HER2

Phase 3 pipeline (2)

trastuzumab deruxtecan (T-DXd) · GI Innovation, Inc. · Oncology
Trastuzumab deruxtecan (T-DXd) is a HER2-targeting antibody-drug conjugate that delivers a DNA crosslinking agent to cancer cells.
Trastuzumab Emtansine for Injection · Shanghai Miracogen Inc. · Oncology
Trastuzumab emtansine targets the HER2 protein on cancer cells and delivers a toxic payload to kill them.

Phase 2 pipeline (1)

Ado-trastuzumab emtamsine · Hoffmann-La Roche · Oncology
Ado-trastuzumab emtansine is a HER2-targeting antibody-drug conjugate that delivers a cytotoxic agent to HER2-positive cancer cells.